« July 2007 | Main | September 2007 »

August 28, 2007

(Bio)piracy in Brazil and elsewhere

Biopiracy=stealing (indigenous) knowledge without proper compensation or credit in return.

Today's New York Times carries a fascinating story about Marc van Roosmalen, a primatologist credited with discovering five species of monkeys and a new primate genus, who has been sentenced to nearly 16 years in a Brazilian jail.

van Roosmalen, one of Time magazine's “Heroes for the Planet” in 2000, is charged with, among other things, taking monkeys from the forest without permits and offering to name new species after wealthy donors -- a practice that is historically common in science, as the Times article points out.

Scientists are rallying to his defense, and 287 of them have signed a petition protesting his sentencing and saying it is indicative of the trend of government repression in Brazil. The government is apparently going overboard in its attempts to prevent biopiracy and, some say, making an example out of van Roosmalen.

This is all well and good. But this article is essentially a rehash of one that appeared in Nature three weeks ago. As anyone who works for scientific journals knows, this is par for the course. Articles that appear in Nature and Science routinely come out slightly modified in newspapers like the Times. And I suppose that's fair enough. But my complaint here is that nowhere in the article is the acknowledgement that Nature first reported the story.

I'll let the irony wash over you.

P.S. I particularly like the picture that ran with the Times article of this snake. Very eye-catching.
monkeys_snake.190

August 23, 2007

Harvard's full coffers

Not that this news will make anyone feel better, but Harvard University is richer than ever before. The unversity's endowment grew more than $5 billion during the 2007 fiscal year to reach a whopping $34.9 billion.

Am I the only one who is shocked by that? Just for comparison, the GDP (or purcashing power) of Burkina Faso, which is as you know, an entire country, home to 14 million people, is $18.76 billion.

The rich of course get richer because they can afford the best. The company that manages the Harvard endowment apaprently posted a 23% return on its investments. I don't suppose they'd consider managing my measly portfolio.

This is your city on drugs

What's the drug of choice in your city? Cocaine? Methamphetamine? Or a simple cup of java?

Turns out it's a lot easier to find out than lurking in alleyways or crashing hipster parties. Scientists from Oregon State University have figured out a way to test an entire city for its drug use — legal and illegal.

The scientists sampled about a teaspoon of water from the sewers — because that's eventually where what people consume ends up — of 10 American cities and tested them for 15 different drugs.

The results, which they presented the Amercan Chemical Society meeting in Boston on Tuesday, are not all that surprising in the end. Here are a few gems:

Most Americans are not too wild and crazy, and their drug of choice is caffeine. People in the midwest are a little more conservative and don't seem to indulge too much in meth use. One city with a heavy gambling industry — Las vegas, anyone? — shows meth levels five times higher than other cities.

I have no doubt New York has its share of drug use, what with all our models, actors and and hyperactive investment bankers. How do you think your city would fare?

You may experience nausea

You know that really, really fast rattling off of side effects at the end of every drug ad on TV? That's there because companies are requried to present a "balanced" picture of the risks and benefits.

But seriously, who can understand a word beyond the rapid-fire "You may experience nausea, headache, blah blah, blah" or read fast enough to decipher the side effects that rapidly scroll down?

Well, apparently the FDA is planning a study with 2,000 people to see whether people are too distracted by the cheery ads to notice the risks. To which I say, Duh. This is such a sadly obvious stalling tactic: "Look, we're doing this study, and we can't take any action till our analysts have told us what it all means."

It's also damage control. Last week, a report in the New England Journal of Medicine said that in 2006, the FDA sent 21 warnings to companies about their ads, down from 142 in 1997. The amount companies have spent on ads went up a whopping 330% during that same time.

Here's another sad little fact that the Associated Press mentioned in its coverage of this issue: The U.S. is one of two industrialized countries that permit TV drug ads -- the other is New Zealand.

When cleanliness is not a good thing

A rather and confusing and counter-intuitive report came out earlier this week, when scientists announced that uncircumcised men who wash their penis after sex are increasing their risk of AIDS.

This is of course contrary to all common sense. Washing after sex, and hygeine generally, is always presented as the way to avoid sexually transmitted infections. So it's not clear why the longer the men waited to wash after sex, the lower their risk of HIV infections became.

Unfortunately, the scientists didn't ask the men how exactly they washed, according to the New York Times, which reported the story on Tuesday. This could be important because the soaps used in Africa are more irritating than the ones in the US, for example, and could be contributing to the bizarre observation. The researchers say it's also possible that vaginal secretions, which are acidic, may be harming the virus. The latter seems unlikely to me — surely if vaginal secretions offered some protection, women would not now be the brunt of the epidemic?

In any case, resolving this seemingly contradictory study is important so public health workers can spread the right message about cleanliness — and not unwittingly put men even more at risk.

August 15, 2007

Unappealing situation

People often ask me what the best part of editing a journal like Nature Medicine is. Well, let me tell you instead about the worst part -- handling manuscript appeals.

It will come as no surprise to you that we turn down a lot of submissions to the journal; somewhere around 90% or more of the papers we receive go back to their authors -- some after our internal review and some others after peer review. Unfortunately, people don't always agree with our decision and ask us to reconsider it.

I say this is unfortunate on several counts. First, as we cannot give priority to a paper we already evaluated, sometimes people have to wait as long as two months to get a new "no" if their arguments don't persuade us to change our decision.

Second, many appeals arrive immediately after we sent our decision. So, they often come from a very angry author who has not had time to see if our reasons to reject the paper actually make sense and who, to put it simply, just wants to vent. Reading an e-mail from or talking over the phone to someone like that is not a pleasant experience.

Third, we take appeal quite seriously, which means that we need to go back to reading the whole paper and the comments from the referees. Sometimes we even get the referees involved once again to clarify some of their points or to comment on the criticisms from the other reviewers. All of this takes time: editorial time, reviewers' time and author's time. In our experience, this is rarely time well spent, as it often simply duplicates what we already did once.

I think that authors often overlook two things about the way we think about appeals. For starters, we view appeals on manuscripts the same way as judges see appeals in a court of law -- they are successful when there is clear evidence that the original sentence was a miscarriage of justice. So, if an author provides evidence that the reviewers' and/or our own arguments to reject the paper are fundamentally flawed, then we reverse our decision. But if the original decision was difficult, and one could provide sound arguments for rejecting or not rejecting the paper, then the appeal is not likely to prosper, the same way that a judge wouldn't reverse a decision if it could have gone either way on the basis of the evidence at the courtroom.

The second aspect that authors often ignore is the fact that, in addition to our responsibility to you as the author, we also have to keep our readers in mind. So, when deciding on whether to reject or not a paper, we also need to take into account whether the manuscript is something that our readers would expect to see in Nature Medicine. And the fact is that, very often, people's view of the appeal of their own work is very different from what we think our readers should get for their money.

In a way, our job is not too dissimilar from that of editors of, say, The Economist or The New Yorker, whose desks are flooded by submissions and pitches, and must ultimately decide on what would be of interest to their subscribers. In our case, of course, after we made that decision, we then lean on our reviewers to comment on technical and other aspects of the work. But this difference notwithstanding, our sense of ownership of the journal is a very important part of our decision-making process.

Going back to the original question that prompted this blog entry, this sense of ownership of the journal is one of the best parts of being an editor.

August 10, 2007

Let's hear it for Texas

While I was traveling in Australia — where most hotels do not seem to have heard of the internet — I missed this rather heartwarming press release from the University of Texas M. D. Anderson Cancer Center.

The center is launching an effort to "recruit, retain, and develop women faculty", led by Elizabeth Travis, the center's first associate vice president for women faculty programs.

About half of medical school students and graduate students are women but a 2006 study by the American Association of Medical Colleges easily shows the "leaky pipeline": women account for 15% of assistant professors, 6% of associate professors and only 4% of full professors. Women also make up just 10% of deans, department and division chairs.

The press release also cites research by Wayne State University linguists in 2003, which showed that the same resume gets a lower evaluation score when attached to a woman's name than when attached to a man's name.

The new program at Anderson aims to recognize those who support women faculty; help women build leadership skills and continue to collect data.

I must say it all sounds promising. I particularly like Travis' comments that all past efforts focused on helping women navigate the system. Rather than "fixing the women," she says, "we need to focus on fixing the academic environment instead."

Hear, hear!

Science down under

I've just returned from a two-week trip to Australia to scout out stories on the state of research in the country. We're planning to run a special issue about Australia science early next year so you can read about it in detail then, but one thing I can tell you is I have never met a bunch of people who take more pride in their country.

Almost every scientist I spoke to had trained abroad and they all said they couldn't imagine living anywhere else. They could go on — and do — for hours about the marvelous lifestyle. Despite the lack of jobs for young scientists, postdocs come back to Australia for the 9-to-5 days, the slower pace, the lack of intense competition all around them.

There's no doubt that despite this lack of intensity, Australia does produce some world-class science. But here's my question for you: Is it possible for scientists to lead this kind of laidback lifestyle and still stay competitive? Or would Australia be a much bigger contender in science if its researchers burned the midnight oil like their American and European counterparts do?

Brazen new world

Talk about chipping away at human rights: lawmakers in Papua, an Indonesian province, want to implant microchips in HIV-positive people.

Yep, you read right. Apparently, the government is fed up with its inability to control the country's AIDS epidemic so the parliament's health committee came up with this scheme to track those who are infected and stop them from transmitting the virus to others. Oh, and they're also calling for mandatory testing of the general population — about 2.4% of whom are believed to be HIV-positive.

Fortunately, saner heads prevailed and the bill was turned down, but no doubt the parliamentarians will come up with more boneheaded schemes.

At one point, they also apparently dicussed tattooing those infected. What would the tattoos say, I wonder? Something along the lines of: "I live in a fascist state"?

A step back for South Africa

South African president Thabo Mbeki, famous for questioning the link between HIV and AIDS, has dismissed Nozizwe Madlala-Routledge, the health minister who seemed to be making a real difference to the country's fight against AIDS.

Madlala-Routledge had replaced previous health minister Manto Tshabalala-Msimang — often called simply "Manto" — who likes to offer beetroot, lemon juice and garlic as remedies for AIDS. After that particular brand of denialism, Madlala-Routledge's tenure was particularly welcome, as I wrote last November.

After her arrival, South Africa announced a comprehensive prevention program and openly acknowledged the gravity of its epidemic. Only a few days ago, the government announced that for the first time in years, its HIV prevalence had fallen — albeit not by much.

It's a shame that the president has so quickly undone the small progress the country had made. No more beetroot and garlic, please!

The imp of the perverse

The article on Lesch-Nyhan syndrome in this week's The New Yorker (An Error in the Code) caught my attention. It's a shame the magazine didn't publish it online, as it's worthwhile reading.

Its subtitle is "What can a rare disorder tell us about human behavior?" Not a lot, I'm afraid.

In a nutshell, people with Lesch-Nyhan lack the enzyme HRPT, which is important for purine metabolism. Patients experience damage to their kidneys, joints and other organs. But the most evident feature of the disease is the patients' drive to inflict physical damage on themselves -- what somewhere in the article is referred to as "the imp of the perverse" in reference to a phrase by Edgar Allan Poe.

It won't come as a surprise that, whereas the kidney and joint damage can be managed in people with the condition, the behavioral problems cannot, at least not very effectively -- as Lesch-Nyhan patients tend to bite their fingers and lips off, restraining their hands and removing their teeth are among the most commonly used ways to keep them from doing so.

What can this grim phenotype tell us about human behavior? A scientist who studies the disorder is quoted as saying that "We all do things that are bad for us... Many people bite their fingernails... There are people who chew their lips nervously. Now let's turn up the volume a little: some people bite their cuticles". And if you keep on "turning up the volume", he argues, you end up with people who bite their fingers to the bone. Surely this is an oversimplification. And even if it's not an oversimplification, it certainly doesn't go too far towards helping us understand what's wrong with these patients.

Another thing that captured my attention was the fact that doctors in Japan and France have managed to eliminate self-mutilation in some of these patients by using deep brain stimulation (DBS), a technique that has yet to be approved for this disease in the U.S. Considering the recent report from American scientists of the man who "woke up" as a result of DBS after spending six years in minimally conscious state, I wonder what's keeping a trial with Lesch-Nyhan patients from starting.

The last thing that caught my attention was the fact that, even though we know what gene is mutated in the disease (HRPT), what part of the brain seems to be affected (the globus pallidus and other parts of the basal ganglia), and what neurotransmitter is reduced (dopamine), there are very few people studying Lesch-Nyhan. During my tenure at Nature Medicine, for example, I don't recall reading a single submission on this topic. So, for those young scientists who are looking for a niche to get their career started (and for those who are tired of drowning in the swamp of Alzheimer or Parkinson disease), Lesch-Nyhan does not look like a bad possibility at all.

August 08, 2007

Mercury rising

Have you had a chance to read our News Feature on the link between vaccination and autism? I encourage you to read it.

When we first discussed the idea of running this story, I didn't think there was much in it. After all, the main articles claiming the existence of such a link had been debunked some time ago. What was news to me, though, was how violent the parents of kids with autism have become. This is quite reminiscent of the strategy that animal activists have taken in the UK to make their point.

In the past, we have written editorials on how important it is for researchers to communicate science to the public, trying to help them distinguish between good and bad science. But cases like this make me wonder: would starting a serious dialogue with the concerned parents really make a difference? I sincerely doubt it. Once your emotional reactions take control of your intellect, arguments aren't likely to make any difference to your point of view.

Being the father of a child with a serious genetic disorder, I have had the opportunity to meet parents of similar kids and see in person how strongly their emotions can cloud their objectivity, particularly at the beginning of their ordeal, when they first get the news that their son or daughter is ill.

There is, however, a clear difference between these parents and the parents of kids with autism; whereas people like me cannot really channel our frustration against anyone other than our own genes, the parents of autistic kids have an easy target in advocates of vaccination schemes to protect kids from diseases that have been eradicated and in scientists who have worked to debunk the vaccine-autism link.

This irony makes their violence even more meaningless than that of animal activists.

August 06, 2007

Why review?

I’m typing this on a glorious sunny Saturday; the chances are that a few of you are also working in the weekend sunshine, reviewing that manuscript for Cell, or Science, or The Journal of Virology, or perhaps even Nature Medicine.

Unlike your counterparts in other professions, however, you’ll be giving your expert advice for free. In our August editorial, we asked what motivates reviewers to spend large portions of their valuable time critiquing other people’s work. It’s a topic close to our hearts. The number of journals is increasing steadily, and scientists simply do not have the time to review every manuscript they are asked to look at.

What makes you decide which papers to review, and for which journals? Which factors are paramount; is it purely the potential importance of the paper that grabs your interest, its relevance to your specific area of research, or does the journal itself weigh into your decision? And if the latter, what are the factors that make you review for particular journals?

Are there any steps that we can take to encourage you to review for us? At Nature Medicine we recently started sending feedback to our reviewers (the other reviewer reports plus an indication of our decision). Are there any other incentives that might predispose you towards one journal or another?

As we discussed in our editorial, good reviewers for our journal know what is required of a Nature Medicine paper. They are fair, objective and can judge the suitability of an advance for a broad vs. specialised readership. We are lucky to have a large pool of trusted experts upon whom we rely. But we are keen to involve less established principal investigators in the reviewing process. This can benefit both sides; the journal gains exposure to the diversity of ideas in a particular field, and the newer investigators, by receiving reviewer feedback, can gauge what their community expects of a paper in a high-profile journal. So please do recommend your colleagues if you must decline a request to review.

On a closely related topic, good reviewers don’t materialize automatically. Can we as a journal participate in the training process? And if so how? Please do comment and tell us your thoughts.

And now that I’ve finished this, I’m off to get an ice-cream. I hope that you too have nearly finished with that paper you’re reviewing and you can get out and enjoy the sunshine while it lasts…

Uploaded on behalf of Clare Thomas, Senior Editor, Nature Medicine